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Abstract (250/250 words): Out of all categories, monoclonal antibody (mAb) therapeutics attract the 
most interest due to their strong therapeutic potency and specificity. Six of the ten top-selling drugs are 
antibody-based therapeutics that will lose patent protection soon. The European Medicines Agency has 
pioneered the regulatory framework for approval of biosimilar products and approved the first biosimilar 
antibodies by the end of 2013. As highly complex glycoproteins with a wide range of micro-variants, 
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mAbs require extensive characterization through multiple analytical methods for structure assessment 
rendering manufacturing control and biosimilarity studies particularly product and time-consuming. Here, 
capillary zone electrophoresis coupled to mass spectrometry by a sheathless interface (CESI-MS) was 
used to characterize marketed reference mAbs and their respective biosimilar candidate simultaneously 
over different facets of their primary structure. CESI-MS/MS data were compared between approved 
mAbs and their biosimilar candidates to prove/disconfirm biosimilarity regarding recent regulation 
directives. Using only a single sample injection of 200 fmol, CESI-MS/MS data enabled 100% amino 
acids (AA) sequence characterization, which allows a difference of even one AA between two samples to 
be distinguished precisely. Simultaneously glycoforms were characterized regarding their structures and 
position through fragmentation spectra and glycoforms semiquantitative analysis was established, 
showing the capacity of the developed methodology to detect up to 16 different glycans. Other 
posttranslational modifications hotspots were characterized while their relative occurrence levels were 
estimated and compared to biosimilars. These results proved the value of using CESI-MS because the 
separation selectivity and ionization efficiency provided by the system allowed substantial improvement 
in the characterization workflow robustness and accuracy. Biosimilarity assessment could be performed 
routinely with a single injection of each candidate enabling improvements in the biosimilar development 
pipeline. 
 INTRODUCTION 
Although monoclonal antibodies (mAbs) were introduced as treatments for disease in the late 1980s 
(muromonab-CD3 was approved in 1986), they currently represent the most rapidly growing category of 
therapeutic molecule.1 Some of their properties naturally explain such success. For example, their 
therapeutic efficiency, reduction of side-effects, favorable pharmacokinetic (PK) and pharmacodynamics 
(PD) lead to an intensive appeal in research and development (R&D) activities regarding this type of 
protein for the last decade.2 Currently more than 40 mAbs have been approved by regulation agencies, 
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such as the US Food and Drug Administration (FDA) or the European Medicine Agency (EMA), and 30 
additional candidates are currently in Phase 3 evaluation.3,4 Their applications are mainly in the field of 
oncology, inflammation, immune mediated disorders and neurological diseases, including Alzheimer’s 
treatments.5, 6 Patents protecting the first generation blockbuster mAbs will expire in the next five years, 
giving the opportunity to many companies to produce “biogeneric versions”. These copies are referred as 
biosimilars or in some cases follow-on biologics. A biosimilar is defined by the EMA as a biological 
medicinal product that contains a version of the active substance of an already authorized original 
biological medicinal product.7 Recombinant mAbs are produced from proprietary cell lines; their 
structural complexity and important micro-variability induced by a given production process explain the 
greater difficulty that generic companies have in producing exactly reproduction of biologic molecules 
compared to small molecules. In the past few years, regulation agencies have worked toward 
establishment of guidelines that, while taking into account such limitations, determine critical quality 
attributes (CQAs) that must be in common between a reference mAb and its biosimilar suggesting that 
their immunogenicity, as well as their PK/PD, should not be significantly different. Those guidelines 
should help demonstrate similarity between a biosimilar candidate compared to the reference product. 
The work by EMA and FDA led to the publication of guidelines7 and to the approval for marketing in the 
EU of a first biosimilar antibody (infliximab), thus paving the way for the whole product class.8 
Biosimilarity assessment includes extensive physicochemical characterization likewise PK and PD study, 
performed in a comprehensive manner. As different structural heterogeneities emerged from comparison 
of a biosimilar candidate with the reference molecule, more complementary studies should be performed 
in order to demonstrate the absence of  toxicological and clinical effect.9 
To perform a complete structural characterization in such a context, innovative analytical 
methodologies have a major role to play for the development and approbation of biosimilars, as well as 
for next generation mAbs. The possibility of obtaining a large variety of structural information over 
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different aspects of the protein (e.g. AA sequence, posttranslational modifications, disulfide bonds, 
glycosylation), in an accurate and robust manner, is obviously necessary and could be an important asset 
for safety and product development. One illustration of that trend is the recent intensification of research 
work aiming to address new issues regarding mAbs characterization.10-12 A crucial point that could 
significantly improve the biosimilar development pipeline is to obtain suitable structural information in 
order to quickly eliminate unsatisfying candidates. Mass spectrometry (MS) has progressively taken an 
important role in the characterization of therapeutic mAbs due to its outstanding selectivity, sensitivity 
and the possibility to obtain structural information. For example, characterization of therapeutic mAbs by 
MS has been applied to product and process development13, 14 and batch consistency assessment.15 
However, MS still needs to be used in concomitance with orthogonal analytical techniques to be able to 
focus on the different facets of the protein including mainly liquid chromatography (LC).16-22 Recently, 
we described a method using capillary zone electrophoresis (CZE) coupled to tandem MS with a 
sheathless interface to perform the simultaneous characterization of several aspects of a protein in one 
injection, including AA sequence and posttranslational modifications (PTMs).23 
The sheathless CE-ESI-MS interface, referred to as CESI-MS, has been developed based on an original 
design proposed by Moini et al.24 Detailed description of this interface has been given by Haselberg et 
al.25 The CESI system has been used to perform successful CE-ESI-MS experiments in proteomics,26, 27 
metabolomics,28 intact proteins,25 therapeutic small molecules29 and as an infusion platform,30 and it 
demonstrated a drastically increased sensitivity compared to sheath-liquid CE-MS interfaces because of 
its low operating flow rates below 100 nL/min. 
In the present work, we developed a transient isotachophoresis CE-ESI-MS/MS methodology, with the 
CESI-MS system, to first obtain the characterization of several mAbs. This extensive characterization 
over different levels of the protein, was performed in a single analysis of each sample. In a second time, 
each mAb was compared to a candidate biosimilar to establish if the methodology developed could be 
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used to assess the biosimilarity between two samples. The comparison was made using the data from a 
single injection of each sample. Transient isotachophoresis (t-ITP) was introduced in this work: t-ITP is 
a preconcentration method widely used with CZE.31 The use of t-ITP enables, in the case of bottom-up 
proteomics, use of sample concentrations similar to those required for nanoLC-MS/MS analysis.26  
The mAbs included are trastuzumab, cetuximab and their respective candidate biosimilars. 
Trastuzumab is a humanized immunoglobulin gamma 1 (IgG-1) directed against the HER2/neu receptor 
overexpressed in around 20-30% of invasive breast cancer (HER2 positive) and more recently to treat 
HER2+ gastric cancer.32, 33 It was first approved as a therapeutic in the US and EU in 1998 and 2000, 
respectively. Trastuzumab is composed of two heavy chains (HC) and two light chains (LC) representing 
a total of 1328 AA. Trastuzumab HC bears an N-glycosylation consensus site on the asparagine (Asn) in 
position Asn-3002 (Figure 1). Cetuximab is human/murine chimeric IgG-1 directed against the epidermal 
growth factor receptor (EGFR) overexpressed in advanced-stage EGFR positive colorectal cancer. 
Cetuximab was approved in the US and EU in 2004 and 2005, respectively. It is composed of two HC 
and two LC as well for a total of 1326 AA and bears two N-glycosylation sites, both present on the HC. 
One is located on the Asn-299 and the other is present on the Asn-8834 (Figure 1). Note that mAbs’ 
glycosylations are subject to extensive characterization and profiling because it significantly influences 
antibody - dependent cell - mediated cytotoxicity (ADCC) and complement dependent cytotoxicity 
(CDC).35-37 
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Figure 1. Schematic representation of trastuzumab and cetuximab. Blue parts of the protein represent the 
constant domain of the mAbs. Yellow parts of the scheme represent the variable domain of the mAbs and 
red parts represent the complementary determining region (CDR). 
 
A tryptic digest of each sample was prepared using an adapted in-solution digestion protocol. The 
digests were then separated and characterized by t-ITP CESI-MS/MS. The peptide mapping was first 
performed using a peptide fragment fingerprinting (PFF) strategy similar to conventional bottom-up 
proteomics. Glycosylations were structurally characterized using MS/MS spectra and a semiquantitative 
profiling was established. Other posttranslational modifications (PTMs) of interest were investigated to 
complete the characterization of mAb samples. Finally trastuzumab and cetuximab CESI-MS/MS 
characterization data were compared to the data obtained for their respective biosimilar candidates in an 
equivalent perspective as required by regulation agencies to assess biosimilarity. This comparison was 
performed in order to determine if the developed t-ITP CESI-MS/MS methodology could be applied to 
demonstrate the biosimilarity between two mAbs in a robust and hastened manner, thereby improving 
biosimilars development pipeline. 
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 RESULTS AND DISCUSSION 
Amino acid sequences characterization. AA sequence is a key criteria for demonstrating the 
biosimilarity of a candidate. Indeed, along with other attributes, regulations require that the AA sequence 
of a candidate is proven to be the same as the reference product in order to be assimilated as biosimilar. 
Each mAb sample was digested by trypsin using an adapted digestion protocol in order to obtain a peptide 
mixture that could be characterized by CESI-MS/MS enabling demonstration/invalidation of the 
biosimilarity of two mAbs. Another aspect of the sample preparation is the source of the sample, reference 
mAbs (trastuzumab and cetuximab) in their commercial formulation were compared to two potential 
biosimilars (trastuzumab-B and cetuximab-B) in development that were sampled directly from the test 
bioreactor and purified, meaning that matrixes were significantly different. Sample preparation requires 
then cancelation of matrix effects, which then renders CESI-MS/MS data completely comparable. 
For trastuzumab, the analysis of the tryptic digest using the CESI-MS/MS method allowed acquisition, 
in a single analysis, of 100% sequence coverage on both HC and LC while injecting only 32 ng of digested 
protein. In a previous work, we demonstrated the capacity to obtain the complete sequence coverage in a 
single analysis using CESI-MS/MS.23 It is important to note, however, that significant improvement of 
the methodology enabled us to obtain the complete AA sequence characterization exclusively through the 
identification of peptides, without miscleavages nor posttranslational modifications, as emphasized in 
Figure 2. Trastuzumab-B was characterized using the same methodology. As shown in Figure 2, the AA 
sequence characterization of this biosimilar allowed demonstration of a complete AA sequence similarity 
to the reference protein except for HC lysine217 (lys-217). Even by considering tryptic peptides with 
miscleavages, the AA lys-217 could not be confirmed, suggesting that this particular AA may be 
substituted in trastuzumab-B compared to the reference mAb. The interpretation of unassigned MS/MS 
spectra allowed us to demonstrate that the AA composing trastuzumab-B in position 217 was an arginine 
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instead of a lysine, as illustrated by the spectra in Figure 3. Several ions pointed out this particular AA 
substitution reinforcing the confidence of this interpretation (Figure 3). From a regulatory standpoint, the 
substitution of one AA does not fit with the highly similar paradigm, and thus trastuzumab-B would not 
be considered biosimilar by either the EMA or FDA. 
 
Figure 2. Sequence coverage obtained by CESI-MS/MS for trastuzumab (left-hand side) and 
trastuzumab-B (right hand side) showing only one amino acid (Lys-217) unidentified in the case of the 
candidate biosimilar. Experimental conditions: bare fused silica capillary (95cm; 30µm i.d.); sample 
mAbs tryptic digest 2.22 µM; injection volume 90nL. 
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Figure 3. Raw MS/MS, extracted from trastuzumab-B CESI-MS/MS analysis, presenting fragmentation 
of ions m/z 517.3095 (1+) and m/z 314.6937 (2+) characterizing the amino acid substitution between 
trastuzumab and its candidate biosimilar. VDKK217VEPK for trastuzumab (G1m17 allotype) and 
VDKR217VEPK in the case of trastuzumab-B (G1m3 allotype). 
 
The same experiment was performed for cetuximab and cetuximab-B head-to-head. Once again, one 
single injection of cetuximab digest allowed the complete characterization of the AA sequence in this case 
as well through peptides without modifications nor miscleavages, demonstrating the robustness of the 
methodology. Cetuximab-B was produced in Chinese hamster ovary cells (CHO) in contrast to the 
reference product, which was produced in mouse myeloma cells (Sp2/0), but based on the same amino-
acid sequence. The comparison of the CESI-MS/MS data, from unique injections of each sample, proved 
the complete equivalence of the AA sequence between cetuximab and its biosimilar candidate. 
The experiment was repeated in three technical replicates and the same results were obtained in a single 
analysis of each mAb sample, demonstrating the reproducibility in term of characterization of the 
developed methodology. The CESI-MS/MS interface demonstrates its capacity to provide an impressive 
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sensitivity, as it allows advanced characterization of the AA sequence using only 32 ng of digested mAbs. 
Even more, the MS/MS data exhibited the capacity to retrieve systematically more than 70% of the y/b 
fragment ions. In the case of trastuzumab, more than 90% of the y/b ions were obtained, which resulted 
into the possibility to unravel the totality of the AA organization over the variable domain. That trend in 
MS/MS spectra quality, even on a MS using a TOF analyzer enabling ions accumulation only on a reduced 
time, is explained by the excellent ionization efficiency when coupling CE to MS through sheathless 
interfacing. Indeed, the low flow rate induced by the electroosmotic flow (< 40 nL/min) and the intrinsic 
characteristics of the CESI interface contribute to the formation of a nano electrospray (nanoESI). The 
nanoESI improves analyte ionization and reduces ion suppression effects, therefore impacting positively 
on MS/MS spectra quality.30 The capacity to obtain the totality of the y/b ions, meaning by deduction the 
AA succession order, for the variable domain could be a huge asset in mAbs development because this 
part of the protein is directly responsible for antigen epitope recognition, and is therefore crucial for mAbs 
potency. 
Glycosylation structural characterization and semiquantitative profiling. Glycosylation is a PTM 
that occurs naturally during excretion of antibodies from the expression system to the extracellular 
medium. It only represents ~ 3% of the total mass of the protein but is subject to extensive studies due to 
its significant influence on effector functions of mAbs, i.e., ADCC and CDC. 
No glycan release was performed during the sample preparation and glycans could be characterized 
directly on the corresponding digested peptide. In the case of the trastuzumab/trastuzumab-B biosimilarity 
study, the injection of the reference mAb allowed identification of 16 different glycoforms borne by 
trastuzumab. Alongside of glycans structural characterization, the semiquantitative glycoforms profiling 
was performed for trastuzumab and its biosimilar candidate as shown in Figure 4. To estimate glycoforms 
distribution, maximum intensities of each charge states of the glycopeptides were considered. The 
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glycoprofiling established for the protein demonstrated the possibility to access lowly abundant glycans 
which is of interest in comparability and biosimilarity studies. 
These results suggest the compatibility between the MS dynamic range and the CE loading capacity. 
Note also that the glycosylation profiling established is consistent to data available in the literature.38 Even 
subtle glycoforms distribution differences between trastuzumab and the candidate biosimilar could be 
distinguished from the results. Trastuzumab-B was also shown to exhibit a rather different glycoforms 
distribution while carrying no glycans containing sialic acid (Figure 4). 
 
Figure 4. Glycoforms semiquantitative analysis results obtained through the CESI-MS/MS data for the 
Fc peptide of trastuzumab/trastuzumab-B and cetuximab/cetuximab-B. Glycoform profiling could be 
compared between original mAbs and their candidate biosimilar. 
 
The cetuximab/cetuximab-B biosimilarity study exhibited different particularities regarding 
glycosylations. Cetuximab bears two N-glycosylation sites on each HC; the first one is located in the Fc/2 
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domain and common to all IgGs, while the second one in the Fd domain.39 Focusing on the glycopeptide 
allowed us to distinguish glycans with regard to their glycosylation sites, which cannot be done when 
using methodologies involving glycans release. In this study as well, glycosylation profiles established 
demonstrated the identification of a significant number of glycosylation on each sites as shown in Figure 
4-B and Figure 5. Significant differences in the glycosylation profile between cetuximab and its biosimilar 
candidate could be characterized, showing the applicability of the method to biosimilarity assessment 
(Figure 4-B). Several cases of hypersensitivity to cetuximab were reported in the literature; the cause of 
that side-effect was related to the galactose-α-1,3-galactose present on the Fd glycosylation site of the 
protein.40 For the marketed version of cetuximab produced in SP2/0 cells, 18 different glycoforms were 
identified, with 88% capped by at least one alpha-1,3-galactose residue, 23% capped by a N-
glycolylneuraminic acid (NGNA) residue and traces of oligomannose. Development of a cetuximab 
biobetter should take into account that side-effect in order to prevent the occurrence of such glycosylation 
and provide an improved product, e.g. by production in CHO cells. Fd glycosylation profiles established 
from CESI-MS/MS data demonstrated that cetuximab-B would not be a suitable biosimilar candidate but 
a possible biobetter. Thus, the glycans identified on the Fd glycosylation site of cetuximab-B were 
significantly different from those present on the innovator mAb. The profile established for cetuximab-B 
therefore demonstrated that the abundance of glycoforms containing galactose-α-1,3-galactose could be 
significantly reduced (Figure 5).  
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Figure 5. Glycoform semiquantitative analysis results regarding Fd domain glycosylation of cetuximab 
and cetuximab-B. 
 
Highly sensitive glycosylation semiquantitation is often performed by removing the glycans using 
specific enzymes.41 Results proved that the methodology used in this study additionally to reduce sample 
treatment, lowering the potentiality of artefacts, allows researchers to specifically locate the glycosylation 
sites and study them independently, with a sensitivity challenging already applied methods. The adopted 
strategy has allowed, concomitant with AA sequence characterization, to demonstrate/disconfirm the 
biosimilarity regarding the glycosylation profile between reference mAbs and their candidate biosimilar. 
PTMs hot-spots comparison study. Other PTMs besides glycosylation must also be considered in 
biosimilarity assessment. PTMs referred as hot-spots are described in the literature as being induced by 
changes of the protein structure. Some of them classified as CQAs may influence the immunogenicity, 
the PK/PD of the protein which explains the analytical developments achieved to perform their 
characterization42, 43. It is therefore necessary to prove that none of those PTMs are over represented in a 
biosimilar candidate, including N-terminal glutamine/glutamic acid cyclization leading to the formation 
of N-terminal pyroglutamic acid (pE), asparagine deamidation (deaN), methionine oxidation (oxiM) and 
aspartic acid isomerization (isoD) on various position depending on the considered mAb.2 CESI-MS/MS 
data were also used to characterize the PTM hot-spots of the different mAbs samples prepared. PTMs 
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occurrence levels were estimated from the data and finally compared between a biosimilar candidate and 
the corresponding originator antibody. 
Data showed that every single PTM hot-spot monitored could be successfully characterized (Table 1). 
The use of electrophoretic separation is particularly pertinent to the characterization of PTMs. Indeed, 
PTMs induced significant change of electrophoretic mobilities between the modified digested peptides 
and its unmodified homologs. Therefore, those peptides could be separated by the electrokinetically 
driven separation of CE, from 0.5 min in the case of deaN to several minutes for pE. The use of CE as a 
separating technique is clearly of great interest. As emphasized in Figure 6, it was possible to separate the 
same peptide differing solely by the conformation of its aspartic acid. The separation in this particular 
modification allows additional information regarding the characterization to be obtained. Indeed, the 
isomerization of aspartic acid does not involve a mass change of the peptide and cannot be identified by 
MS using a time-of-flight (TOF) analyzer. Moreover, the ability to separate, upfront to MS analysis, a 
peptide that experienced chemical modifications from the same peptide without modification allows 
sensitivity to be maximized. In the case of co-migration, those peptides would compete against each other 
during the ionization process. Signal is improved by their separation and occurrence levels accuracy 
theoretically optimal. Specificity of CE separation enables the separation of digested peptides 
experiencing aspartic acid isomerization; that characteristic is particularly valuable as the characterization 
of such modification requires particular methods giving access solely to this information,21 in contrast, 
here the study of aspartic acid isomerization could be incorporated within the framework of the overall 
primary structure characterization. The excellent MS/MS spectra quality obtained was particularly useful 
for PTM hot-spots characterization as it was possible to point out precisely the AA affected by the 
modification. PTM hot-spots semiquantitative measure was performed for each sample and occurrence 
levels were compared between the reference mAb and its respective candidate biosimilar as emphasized 
in Table 1 and 2. In this part, relative occurrence levels were estimated from the maximum intensities of 
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the ions corresponding to the modified peptides compared to the abundance of the corresponding 
unmodified peptide. 
 
Figure 6. Extracted Ion Electropherogram (EIE) corresponding to m/z (839.408, 2+) for digested peptide 
HT22 (position 278-291) experiencing aspartic acid isomerization. 
 
In the context of the trastuzumab/trastuzumab-B biosimilarity study, results showed that endogenous 
deamidation due to proteolytic digestion conditions could be significantly controlled as several 
deamidation sites exhibited modifications levels below 7% and even 4% for deaN55 (Table 1). Results 
demonstrated the capacity of this methodology to distinguish significant variation of modification levels. 
Therefore, results showed that isoD-170 (LC) abundance was superior to 13.4% in trastuzumab while its 
candidate biosimilar exhibited only 7.1% on this modification (Table 1). A similar trend could also be 
unraveled with the presented results for isoD-167 (LC). These high levels of modifications were correlated 
to the prolonged time the sample of reference trastuzumab had been stored. Regarding deaN, results of 
trastuzumab/trastuzumab-B showed dissimilarities for deaN-387 (HC) only, indeed trastuzumab-B 
exhibited less than 1% of this modification. OxiM results obtained from this study proved similar level of 
oxidation on the designated sites (Table1). 
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position sequence PTM 
Trastuzumab 
distribution 
Trastuzumab-B 
distribution 
unmodif modif unmodif modif 
1 -19 EVQLVESGGGLVQPGGSLR E1 / pE1 98.2 1.8 97.3 2.7 
51 - 59 IYPTNGYTR N55 / deaN55 89.4 10.6 92.3 7.7 
99 - 124 WGGDGFYAMDYWGQGTLVTVSSASTK D102 / isoD102 84.9 15.1 86.0 14.0 
252 - 258 DTLMISR M255 / oxiM255 95.3 4.7 94.5 5.5 
259 - 277 TPEVTCVVVDVSHEDPEVK D272 / isoD272 94.4 5.6 94.5 5.5 
278 - 291 FNWYVDGVEVHNAK D283 / isoD283 92.0 8.0 96.5 3.5 
374 - 395 GFYPSDIAVEWESNGQPENNYK N387 / deaN387 85.8 14.3 100.0 0.0 
420 - 442 WQQGNVFSCSVMHEALHNHYTQK M431 / oxiM431 97.8 2.2 95.2 4.8 
396 - 412 TTPPVLDSDGSFFLYSK D404 / isoD404 93.0 7.0 93.9 6.1 
       
25 - 42 ASQDVNTAVAWYQQKPGK N30 / deaN30 96.1 3.9 96.0 4.0 
150 - 169 VDNALQSGNSQESVTEQDSK D167 / isoD167 64.0 36.0 91.6 8.4 
170 - 183 DSTYSLSSTLTLSK D170 / isoD170 86.6 13.4 92,9 7.1 
Table 1. Table summarizing the study regarding PTM hotspots occurrence levels for 
trastuzumab/trastuzumab-B obtained by CESI-MS/MS for each tryptic digest, modification levels 
(distribution % intact / % modification) were determined through signal intensity for each targeted PTM. 
 
Relative occurrence levels of PTM hot-spots were also studied and compared in the case of 
cetuximab/cetuximab-B. Results obtained were compiled in Table 2. As in the first study, results obtained 
allowed successful characterization of each of the PTMs hot-spots present on cetuximab. Results of the 
semiquantitative analysis regarding PTMs hot-spots occurrence were compared. Notably, both mAbs 
demonstrated specific characteristics supporting their similarity: N-terminal glutamine (Gln) cyclization 
was shown to be complete because the intact peptide could not be detected in samples of either mAbs. 
This trend could also be confirmed on the HC for isoD403 and deaN158 (Table 2); indeed those 
modifications exhibited absolutely no occurrence in cetuximab or its candidate biosimilar, illustrating the 
similarity of those proteins on such specific aspect. Cetuximab, as opposed to cetuximab-B, demonstrated 
slightly superior deamidation levels in the case of deaN172 and deaN386 for the HC and deaN41 on the LC 
(Table 2), which were correlated with a longer conservation period for the reference mAb sample. 
However, these results illustrate the sensitivity of the method, which allows only minor variations in 
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PTMs occurrence levels to be distinguished. Regarding the biosimilarity assessment of PTM hot-spots, 
results did not demonstrated overexpressed modifications for the biosimilar candidate compared to their 
respective innovator mAbs showing they could comply with the guidelines on this particular aspect. 
position sequence PTM 
Cetuximab 
distribution 
Cetuximab-B 
distribution 
unmodif modif unmodif modif 
1 -5 QVQLK Q1 / pQ1 100.0 0.0 100.0 0.0 
150 - 212 
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTK 
N161 / deaN161 25.6 74.4 59.5 40.5 
277 - 290 FNWYVDGVEVHNAK D282 / isoD282 95.2 4.8 96.3 3.7 
373 - 394 GFYPSDIAVEWESNGQPENNYK N386 / deaN386 45.6 54.4 95.7 4.3 
395 - 411 TTPPVLDSDGSFFLYSK D403 / isoD403 100.0 0.0 100.0 0.0 
       
40 - 45 TNGSPR N41 / deaN41 87.8 12.2 94.7 5.3 
150 - 169 VDNALQSGNSQESVTEQDSK N158 / deaN158 96.6 3.4 100.0 0.0 
Table 2. Table summarizing the study regarding PTM hotspots occurrence levels for cetuximab/ 
cetuximab-B. Using the CESI-MS/MS data for each tryptic digest, modification levels (distribution % 
intact / % modification) were determined through signal intensity for each targeted PTM. 
 
The characterization strategy developed in this study involved the use of CESI-MS/MS analysis. Data 
obtained from only one injection of each sample tryptic digest allowed characterization of each mAbs 
simultaneously over several levels defining their primary structure: AA sequence, glycosylation 
structure/relative abundance and specific PTMs hot-spots. The purpose was to study the biosimilarity 
between two approved mAbs (trastuzumab and cetuximab) and two respective biosimilar candidates. 
Biosimilarity study results unraveled that in both cases, biosimilar candidates would hardly be considered 
as such according to current regulations. In the case of trastuzumab-B, one AA difference compared to 
the original mAb led to this conclusion, while in the case of cetuximab-B, major glyco-profile variations 
were highlighted. Among the biosimilarity assessments performed successfully for each mAbs, data 
collected during the CESI-MS/MS analysis pointed out specifically which attribute of the protein did not 
comply with the reference mAb giving precious information from an R&D perspective. For example, the 
difference of one AA for trastuzumab-B strongly supports the need of re-engineering of the vector to 
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produce the right allotype.44 However, in the case of cetuximab-B, each aspect of the primary structure of 
the mAb demonstrated the biosimilarity except for the glycosylation. Yet recent advances in mAbs 
glycoengineering permits optimization of the mAbs glycoform expression, thereby suppressing undesired 
glycosylations.45, 46  
In summary, the CESI-MS/MS strategy developed in the context of this study appeared to be fully 
compatible with use as an orthogonal technique concomitantly to the now commonly used analytical 
techniques for characterization of mAbs, biosimilar, biobetters and, more generally, biotherapeutic 
proteins. 
 
 CONCLUSIONS 
We report here an innovative strategy involving CE coupled to high resolution tandem MS to 
characterize mAbs simultaneously over different angles of their primary structure, in order to perform 
biosimilarity assessments between approved mAbs (trastuzumab and cetuximab) and candidate 
biosimilars. Prior to analysis, samples were digested by trypsin using an adapted in-solution digestion 
protocol allowing improvement in digestion yield and a standardized final sample content compatible 
with CE separation. The analysis of each sample allowed establishment of the similarity/dissimilarities 
concerning AA sequence between several approved mAbs and their respective biosimilar candidates. 
The sensitivity and MS/MS spectra quality obtained, mainly supported by the instrumental setting used 
in this work, enabled AA sequence characterization on an unprecedented level as 100% sequence 
coverage could be obtained in a single analysis through identification of only tryptic peptides without 
miscleavages or PTMs. Furthermore more than 70% of the y/b ions could be systematically retrieved, 
providing detailed structural data over this aspect of the protein. Along with this characterization, 
structural and semiquantitative analysis of the glycoforms could be performed, which demonstrated the 
capacity of the method to locate precisely different glycosylations sites. The glycoforms profiling 
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obtained demonstrated the capacity of the established methodology to detect quite low abundance glycans, 
enabling the detection of potentially undesired glycoforms. Likewise the profiling accuracy was also 
highlighted as relative abundances obtained could be correlated to other methods. CESI-MS/MS data 
enabled subtle differences in glycoforms distribution between reference mAbs and their candidate 
biosimilars to be distinguished, proving that the dynamic range achievable with CE-ESI-MS coupling is 
fully compatible with this type of analytical problem. Finally, specific PTMs hot-spots were characterized 
using the very same CESI-MS/MS data used to characterize mAbs samples previously; results 
demonstrated the capacity of the method to characterize precisely the targeted sites. 
The sensitivity provided by the CESI-MS system allowed, in most cases, the precise identification of 
the AA affected by the PTMs even in the circumstances of weakly abundant modifications. CE separation 
specificity proved valuable because peptides with chemical modification, as weak as aspartic acid 
isomerization, could be separated, enabling their concomitant characterization. The results illustrated the 
capacity of the method to observe differences in modification levels between the reference mAb samples 
and their respective candidate biosimilars studied. Data obtained from CESI-MS/MS analysis established 
dissimilarities that existed amongst the candidate biosimilars compared to the approved mAbs, 
demonstrating the ability of the developed methodology to address such analytical issues in a structured 
and comprehensive way while easing sample treatment and reducing the number of experiment required. 
Furthermore, results permitted identification of precisely which aspects of the candidate antibody did not 
comply with their assignment as biosimilars providing important structural information that could be used 
to strategically plan subsequent R&D work. This study illustrates without ambiguity the possibility of 
using CE coupled to MS as an orthogonal technique, along with techniques routinely applied, to address 
complex analytical issues such as mAbs biosimilarity assessment, and points out more generally the 
capacity of this type of coupling to characterize biotherapeutic proteins. 
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 MATERIALS & METHODS 
Materials. Chemicals used were of analytical grade or high purity grade and purchased from Sigma-
Aldrich (Saint Louis, MO, USA). Water used to prepare buffers and sample solutions was obtained using 
an ELGA purelab UHQ PS water purification system (Bucks, UK). Trastuzumab and cetuximab samples 
are the EMA approved products and formulation purchased from Roche (Penzberg, GE) and Merck KGaA 
(Darmstadt, GE) respectively. The biosimilar versions were produced at the Centre d’Immunologie Pierre 
Fabre (Saint Julien en Genevois, FR) for analytical methods development. Marketed mAbs were stored 
at 4°C for one year before characterization while biosimilar versions was analyzed soon after their 
reception (approximately 2 months), otherwise all samples were stored at 4°C. RapiGest SF surfactant 
was purchased from Waters (Milford, MA, USA). 
Sample preparation. A volume corresponding to 100 µg of protein were used. Samples were first 
diluted using milliQ water to a final concentration of 6.7 µg/µL. Samples were then diluted using 0.1% 
RapiGest surfactant to reach a final concentration of 3.35 µg/µL and heated to 40°C during 10 min. 
Dithiothreitol (DTT) was added to the sample to a final concentration of 25 mM. Samples were then 
heated for a 5 min incubation at 95°C. After being cooled to room temperature (RT), iodoacetamide (IDA) 
was added to the sample to a final concentration of 10 mM and samples were kept in the dark for 20 min 
to allow alkylation of cysteines (Cys). A volume of 1 µL of trypsin (0.5µg/µL) was added to the sample 
which was left at room temperature for 3h and another volume of 1µL was added after this time. Digestion 
was performed overnight at 37°C. After digestion completion, 1% (v/v) formic acid (FA) was added to 
the samples, which were left at RT in order to cleave the surfactant. Samples were finally diluted to a final 
concentration of 2.2 µM of protein using ammonium acetate 50 mM (pH 4.0). 
Capillary electrophoresis. The CE separations were performed with a PA 800 plus capillary 
electrophoresis system from Beckman Coulter equipped with a temperature controlled autosampler and a 
power supply able to deliver up to 30 kV. Hyphenation was carried out using a CESI prototype made 
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available by Sciex separation (Brea, CA, USA). Prototype of bare fused-silica capillaries (total length 100 
cm; 30 μm i.d.) with a characteristic porous tip on its final 3 cm supplied by Sciex separation, a second 
capillary (total length 80 cm; 50 μm i.d.) filled during experiments with BGE allows electric contact. New 
capillaries were flushed at 75 psi (5.17 bar) for 10 min with methanol, 10 min with 0.1 M sodium 
hydroxide, then 10 min with 0.1 M hydrochloric acid and water for 20 min. Finally, the capillary was 
flushed 10 min at 75 psi with 10% acetic acid, which is the BGE used for the separation. Hydrodynamic 
injection (410 mbar for 1 min) corresponding to a total volume of 90 nL of sample injected was used. 
Separations were performed using a voltage of +20 kV. 
Mass spectrometry. For antibody characterization, the CESI system was hyphenized to a 5600 
TripleTOF mass spectrometer (ABSciex, Darmstadt, Germany). The 5600 MS is equipped with a hybrid 
analyzer composed of quadrupoles followed by a time-of-flight (TOF) analyzer. ESI source parameters 
were set as follows: ESI voltage -1.75kV, gas supplies (GS1 and GS2) were deactivated, source heating 
temperature 150°C and curtain gas value 5. Experiments were performed in Top15 information dependent 
acquisition (IDA), accumulation time was 250 msec for MS scans and 100 msec for MS/MS scans leading 
to a total duty cycle of 1.75 sec. Mass/charge (m/z) range was set to 100-2000 in MS and 50-2000 in 
MS/MS. Using those parameters, the mean resolution provided by the instrument is 40000 in MS (m/z 
485.251) and 25000 in MS/MS (m/z 345.235). 
MS/MS data analysis. Data obtained from the CESI-MS/MS experiments were analyzed using 
Peakview software (ABSciex, Darmstadt, Germany). Tryptic peptides (without miscleavages or PTMs 
except cys carbamidomethylation) were determined theoretically from the mAbs’ amino acid sequences 
available through literature.23, 47 Additional peptides were identified using Mascot search engine provided 
by Matrix science; tryptic cleavage rules were applied. Carbamidomethylation of cysteine (+57.02 Da), 
N-deamidation of aspartic/isoaspartic acid (+0.985 Da) or succinimide intermediate (-17.03 Da), 
methionine oxidation (+15.99 Da) and N-terminal glutamic acid cyclization (-17.02 Da) were selected as 
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variable modifications. The mass tolerance for precursor ions was set to ± 5 ppm and ±0.05 Da for 
fragmentation ions. 
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 FIGURE LEGENDS 
Figure 1. Schematic representation of trastuzumab and cetuximab. Blue parts of the protein 
represent the constant domain of the mAbs. Yellow parts of the scheme represent the variable 
domain of the mAbs and red parts represent the complementary determining region (CDR). 
 
Figure 2. Sequence coverage obtained by CESI-MS/MS for trastuzumab (left-hand side) and 
trastuzumab-B (right hand side) showing only one amino acid (Lys-217) unidentified in the case 
of the candidate biosimilar. Experimental conditions: bare fused silica capillary (95cm; 30µm i.d.); 
sample mAbs tryptic digest 2.22 µM; injection volume 90nL. 
 
Figure 3. Raw MS/MS, extracted from trastuzumab-B CESI-MS/MS analysis, presenting 
fragmentation of ions m/z 517.3095 (1+) and m/z 314.6937 (2+) characterizing the amino acid 
substitution between trastuzumab and its candidate biosimilar. VDKK217VEPK for trastuzumab 
(G1m17 allotype) and VDKR217VEPK in the case of trastuzumab-B (G1m3 allotype). 
 
Figure 4. Glycoforms semiquantitative analysis results obtained through the CESI-MS/MS data 
for the Fc peptide of trastuzumab/trastuzumab-B and cetuximab/cetuximab-B. Glycoform 
profiling could be compared between original mAbs and their candidate biosimilar. 
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Figure 5. Glycoform semiquantitative analysis results regarding Fd domain glycosylation of 
cetuximab and cetuximab-B. 
 
Figure 6. Extracted Ion Electropherogram (EIE) corresponding to m/z (839.408, 2+) for digested 
peptide HT22 (position 278-291) experiencing aspartic acid isomerization. 
 
Table 1. Table summarizing the study regarding PTM hotspots occurrence levels for 
trastuzumab/trastuzumab-B obtained by CESI-MS/MS for each tryptic digest, modification levels 
(distribution % intact / % modification) were determined through signal intensity for each targeted 
PTM. 
 
Table 2. Table summarizing the study regarding PTM hotspots occurrence levels for cetuximab/ 
cetuximab-B. Using the CESI-MS/MS data for each tryptic digest, modification levels 
(distribution % intact / % modification) were determined through signal intensity for each targeted 
PTM. 
 
 
